Significance of Early Genetic Testing in HRR-Mutated mCRPC Highlighted by Real-World Observations
January 26th 2024Individuals diagnosed with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC) receiving olaparib face a critical requirement for timely and consistent genetic testing to enhance treatment outcomes.
Read More
Analysis of Subsequent Therapies Confirms OS Benefit of Darolutamide in mHSPC
January 25th 2024A post hoc sensitivity analysis that counted use of subsequent therapies in patients censored from primary overall survival follow-up favored darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Read More
High-Dose Radiation Plus Long-Term ADT Improves Survival in High-Risk Prostate Cancer
January 25th 2024A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.
Read More
Enhanced Progression-Free Survival: Cabozantinib Combination Outperforms NHT in Metastatic CRPC
January 25th 2024Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.
Read More
Abiraterone, Prednisone, Apalutamide Improves Prostate Cancer Outcomes, Leaves HRQoL Unaffected
January 25th 2024Oncological outcomes improved with the addition of abiraterone acetate (Zytiga) plus prednisone (AAP) and apalutamide (Erleada) after radical prostatectomy and did not significantly affect health-related quality of life.
Read More
Prior ERBT Did Not Increase Hematological Toxicity in Ra-223-Treated mCRPC
January 25th 2024Prior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.
Read More
HRRm Tester Underutilized for mCRPC in the Real-World Setting
January 25th 2024While germline and somatic testing is standard of care in the metastatic castration-resistant prostate cancer setting, it is still underutilized in the real world, leading to negative impacts on therapeutic offerings.
Read More
Adding Darolutamide to ADT May Reduce Hospitalizations But Longer Stays in mHSPC
January 25th 2024Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.
Read More
Promising Activity in MSS CRC with Innovative Drug Combined with Bevacizumab and Chemotherapy
January 20th 2024In the DeFianCe trial, the combination of DKN-01 with bevacizumab and chemotherapy is being investigated to assess the potential clinical benefits for patients diagnosed with microsatellite stable colorectal adenocarcinoma.
Read More
First-Line Nivolumab Plus Ipilimumab Demonstrates Superior PFS in mCRC
January 20th 2024Results from the phase 3 CheckMate-8HW trial support first-line treatment with nivolumab plus ipilimumab as a standard-of-care option for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer.
Read More
Regorafenib Discontinuation More Likely With Poor Liver Function in Liver Cancer
January 19th 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious adverse effects leading to regorafenib treatment discontinuation, researchers have found.
Read More